Integra Lifesciences Holdings (IART) Depreciation & Amortization (CF) (2009 - 2026)

Integra Lifesciences Holdings' Depreciation & Amortization (CF) history runs 18 years deep, the most recent figure standing at $38.4 million for Q1 2026.

• In Q1 2026, Depreciation & Amortization (CF) rose 3.34% year-over-year to $38.4 million; the TTM figure through Mar 2026 stood at $153.1 million (up 3.77% YoY), while the FY2025 annual figure was $151.8 million, up 7.76% from the prior year.
• Depreciation & Amortization (CF) came in at $38.4 million for Q1 2026 at Integra Lifesciences Holdings, roughly flat from $38.4 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $38.5 million in Q3 2025 to a low of $29.5 million in Q3 2022.
• A 5-year average of $33.7 million and a median of $31.1 million in 2023 frame the typical range for Depreciation & Amortization (CF).
• Across the five-year window, Depreciation & Amortization (CF) declined 4.07% in 2022 and gained 21.66% in 2025, its largest moves.
• Integra Lifesciences Holdings' Depreciation & Amortization (CF) stood at $29.5 million in 2022, then grew by 5.05% to $31.0 million in 2023, then increased by 21.31% to $37.6 million in 2024, then rose by 2.24% to $38.4 million in 2025, then changed by 0.0% to $38.4 million in 2026.
• According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $38.4 million, $38.4 million, and $38.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison